Microbix Biosystems Inc. (MBXBF)
USD 0.27
(10.2%)
USD 0.27
(10.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.02 Million CAD | 34.39% |
| 2022 | 8.2 Million CAD | -20.11% |
| 2021 | 10.27 Million CAD | 14.42% |
| 2020 | 8.97 Million CAD | -1.25% |
| 2019 | 9.09 Million CAD | 1.51% |
| 2018 | 8.95 Million CAD | -20.48% |
| 2017 | 11.26 Million CAD | 13.13% |
| 2016 | 9.95 Million CAD | 0.87% |
| 2015 | 9.87 Million CAD | 21.0% |
| 2014 | 8.15 Million CAD | 16.62% |
| 2013 | 6.99 Million CAD | -25.47% |
| 2012 | 9.38 Million CAD | 8.33% |
| 2011 | 8.66 Million CAD | -0.01% |
| 2010 | 8.66 Million CAD | 12.87% |
| 2009 | 7.67 Million CAD | 9.93% |
| 2008 | 6.98 Million CAD | 98.42% |
| 2007 | 3.51 Million CAD | 41.96% |
| 2006 | 2.47 Million CAD | 109.77% |
| 2005 | 1.18 Million CAD | 8.3% |
| 2004 | 1.09 Million CAD | 10.18% |
| 2003 | 990.3 Thousand CAD | 64.25% |
| 2002 | 602.92 Thousand CAD | -33.67% |
| 2001 | 908.94 Thousand CAD | -20.48% |
| 2000 | 1.14 Million CAD | 14.3% |
| 1999 | 1 Million CAD | -50.0% |
| 1998 | 2 Million CAD | 81.82% |
| 1997 | 1.1 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 9.71 Million CAD | -4.48% |
| 2024 Q2 | 10.16 Million CAD | 7.22% |
| 2024 Q1 | 9.48 Million CAD | -14.03% |
| 2023 FY | 11.02 Million CAD | 34.39% |
| 2023 Q2 | 9.82 Million CAD | 6.46% |
| 2023 Q3 | 11.65 Million CAD | 18.54% |
| 2023 Q1 | 9.23 Million CAD | 12.5% |
| 2023 Q4 | 11.02 Million CAD | -5.35% |
| 2022 FY | 8.2 Million CAD | -20.11% |
| 2022 Q2 | 9.13 Million CAD | 1.16% |
| 2022 Q3 | 8.55 Million CAD | -6.37% |
| 2022 Q1 | 9.02 Million CAD | -12.12% |
| 2022 Q4 | 8.2 Million CAD | -4.03% |
| 2021 Q1 | 9.24 Million CAD | 2.94% |
| 2021 Q2 | 9.74 Million CAD | 5.4% |
| 2021 Q3 | 9.14 Million CAD | -6.07% |
| 2021 FY | 10.27 Million CAD | 14.42% |
| 2021 Q4 | 10.27 Million CAD | 12.28% |
| 2020 Q1 | 9.77 Million CAD | 7.52% |
| 2020 FY | 8.97 Million CAD | -1.25% |
| 2020 Q3 | 8.93 Million CAD | 2.14% |
| 2020 Q4 | 8.97 Million CAD | 0.53% |
| 2020 Q2 | 8.74 Million CAD | -10.56% |
| 2019 FY | 9.09 Million CAD | 1.51% |
| 2019 Q1 | 9.66 Million CAD | 7.85% |
| 2019 Q2 | 9.61 Million CAD | -0.5% |
| 2019 Q3 | 9.78 Million CAD | 1.76% |
| 2019 Q4 | 9.09 Million CAD | -7.05% |
| 2018 FY | 8.95 Million CAD | -20.48% |
| 2018 Q2 | 8.55 Million CAD | -4.91% |
| 2018 Q3 | 9.69 Million CAD | 13.36% |
| 2018 Q4 | 8.95 Million CAD | -7.65% |
| 2018 Q1 | 8.99 Million CAD | -20.11% |
| 2017 Q4 | 11.26 Million CAD | 8.9% |
| 2017 Q2 | 10.25 Million CAD | 6.79% |
| 2017 FY | 11.26 Million CAD | 13.13% |
| 2017 Q1 | 9.6 Million CAD | -3.54% |
| 2017 Q3 | 10.34 Million CAD | 0.85% |
| 2016 Q2 | 9.93 Million CAD | 3.75% |
| 2016 Q4 | 9.95 Million CAD | -7.48% |
| 2016 Q1 | 9.57 Million CAD | -2.96% |
| 2016 Q3 | 10.76 Million CAD | 8.29% |
| 2016 FY | 9.95 Million CAD | 0.87% |
| 2015 FY | 9.87 Million CAD | 21.0% |
| 2015 Q1 | 8.22 Million CAD | 0.88% |
| 2015 Q4 | 9.87 Million CAD | 8.25% |
| 2015 Q2 | 9.11 Million CAD | 10.83% |
| 2015 Q3 | 9.11 Million CAD | -0.02% |
| 2014 Q4 | 8.15 Million CAD | -0.49% |
| 2014 Q1 | 6.6 Million CAD | -5.58% |
| 2014 FY | 8.15 Million CAD | 16.62% |
| 2014 Q3 | 8.19 Million CAD | 3.68% |
| 2014 Q2 | 7.9 Million CAD | 19.72% |
| 2013 Q2 | 9.01 Million CAD | 1.05% |
| 2013 Q4 | 6.99 Million CAD | -21.18% |
| 2013 Q3 | 8.87 Million CAD | -1.54% |
| 2013 Q1 | 8.92 Million CAD | -4.95% |
| 2013 FY | 6.99 Million CAD | -25.47% |
| 2012 FY | 9.38 Million CAD | 8.33% |
| 2012 Q4 | 9.38 Million CAD | 12.19% |
| 2012 Q3 | 8.36 Million CAD | -1.49% |
| 2012 Q2 | 8.49 Million CAD | -1.84% |
| 2012 Q1 | 8.65 Million CAD | -0.14% |
| 2011 Q2 | 8.66 Million CAD | 11.09% |
| 2011 FY | 8.66 Million CAD | -0.01% |
| 2011 Q4 | 8.66 Million CAD | -0.75% |
| 2011 Q3 | 8.72 Million CAD | 0.68% |
| 2011 Q1 | 7.8 Million CAD | -9.93% |
| 2010 Q3 | 7.98 Million CAD | 4.08% |
| 2010 Q2 | 7.67 Million CAD | -1.16% |
| 2010 Q1 | 7.76 Million CAD | 1.12% |
| 2010 Q4 | 8.66 Million CAD | 8.51% |
| 2010 FY | 8.66 Million CAD | 12.87% |
| 2009 FY | 7.67 Million CAD | 9.93% |
| 2009 Q3 | 7.83 Million CAD | 0.52% |
| 2009 Q4 | 7.67 Million CAD | -2.07% |
| 2009 Q1 | 7.05 Million CAD | 1.04% |
| 2009 Q2 | 7.79 Million CAD | 10.53% |
| 2008 Q2 | 3.89 Million CAD | 6.56% |
| 2008 Q1 | 3.65 Million CAD | 3.79% |
| 2008 FY | 6.98 Million CAD | 98.42% |
| 2008 Q4 | 6.98 Million CAD | 32.9% |
| 2008 Q3 | 5.25 Million CAD | 34.99% |
| 2007 Q4 | 3.51 Million CAD | 16.95% |
| 2007 FY | 3.51 Million CAD | 41.96% |
| 2007 Q1 | 2.54 Million CAD | 2.57% |
| 2007 Q2 | 2.93 Million CAD | 15.49% |
| 2007 Q3 | 3 Million CAD | 2.47% |
| 2006 Q4 | 2.47 Million CAD | 23.6% |
| 2006 FY | 2.47 Million CAD | 109.77% |
| 2006 Q2 | 1.87 Million CAD | 34.86% |
| 2006 Q1 | 1.39 Million CAD | 17.91% |
| 2006 Q3 | 2 Million CAD | 6.73% |
| 2005 Q1 | 1.01 Million CAD | -6.62% |
| 2005 Q2 | 1.06 Million CAD | 4.77% |
| 2005 FY | 1.18 Million CAD | 8.3% |
| 2005 Q4 | 1.18 Million CAD | 10.69% |
| 2005 Q3 | 1.06 Million CAD | 0.01% |
| 2004 Q3 | 1.31 Million CAD | 33.72% |
| 2004 Q2 | 982.81 Thousand CAD | 11.6% |
| 2004 Q4 | 1.09 Million CAD | -16.97% |
| 2004 FY | 1.09 Million CAD | 10.18% |
| 2004 Q1 | 880.66 Thousand CAD | -11.07% |
| 2003 Q4 | 990.3 Thousand CAD | -12.77% |
| 2003 Q2 | 992.19 Thousand CAD | -11.01% |
| 2003 Q1 | 1.11 Million CAD | 84.93% |
| 2003 FY | 990.3 Thousand CAD | 64.25% |
| 2003 Q3 | 1.13 Million CAD | 14.42% |
| 2002 Q3 | 732.37 Thousand CAD | -6.26% |
| 2002 FY | 602.92 Thousand CAD | -33.67% |
| 2002 Q2 | 781.3 Thousand CAD | -11.94% |
| 2002 Q1 | 887.26 Thousand CAD | -2.39% |
| 2002 Q4 | 602.92 Thousand CAD | -17.68% |
| 2001 Q1 | 1.13 Million CAD | -0.45% |
| 2001 FY | 908.94 Thousand CAD | -20.48% |
| 2001 Q3 | 1 Million CAD | -5.47% |
| 2001 Q4 | 908.94 Thousand CAD | -9.42% |
| 2001 Q2 | 1.06 Million CAD | -6.71% |
| 2000 FY | 1.14 Million CAD | 14.3% |
| 2000 Q1 | 900 Thousand CAD | -10.0% |
| 2000 Q4 | 1.14 Million CAD | 14.3% |
| 2000 Q3 | 1 Million CAD | -16.67% |
| 2000 Q2 | 1.2 Million CAD | 33.33% |
| 1999 Q2 | 1.2 Million CAD | -7.69% |
| 1999 Q4 | 1 Million CAD | -16.67% |
| 1999 Q3 | 1.2 Million CAD | 0.0% |
| 1999 Q1 | 1.3 Million CAD | -35.0% |
| 1999 FY | 1 Million CAD | -50.0% |
| 1998 Q4 | 2 Million CAD | 81.82% |
| 1998 FY | 2 Million CAD | 81.82% |
| 1998 Q3 | 1.1 Million CAD | -21.43% |
| 1998 Q2 | 1.4 Million CAD | 16.67% |
| 1998 Q1 | 1.2 Million CAD | 9.09% |
| 1997 Q2 | 900 Thousand CAD | 0.0% |
| 1997 Q3 | 1.1 Million CAD | 22.22% |
| 1997 Q1 | 900 Thousand CAD | 0.0% |
| 1997 FY | 1.1 Million CAD | 0.0% |
| 1997 Q4 | 1.1 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -239.392% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 79.311% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2516.075% |
| SQZ Biotechnologies Company | 50.03 Million USD | 77.96% |
| Intellipharmaceutics International Inc. | 12 Million USD | 8.163% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 84.782% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 81.312% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -186.35% |
| Marizyme, Inc. | 26.67 Million USD | 58.657% |
| Genus plc | 485 Million USD | 97.726% |
| Pharming Group N.V. | 244.07 Million USD | 95.481% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -448.648% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -338.279% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -190.225% |
| ContraFect Corporation | 32.53 Million USD | 66.098% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -188.128% |
| IMV Inc. | 37.93 Million USD | 70.926% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 6.365% |
| ONE Bio Corp. | 27.49 Million USD | 59.89% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 85.754% |
| Mesoblast Limited | 188.44 Million USD | 94.148% |
| MultiCell Technologies, Inc. | 1617.67 USD | -681654.437% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 86.702% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.168% |
| Neon Bloom, Inc. | 1.22 Million USD | -799.398% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -114.311% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -15.096% |
| Biomind Labs Inc. | 1.49 Million USD | -635.917% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -21.967% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 40.073% |
| Skye Bioscience, Inc. | 14.07 Million USD | 21.629% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -669.15% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -88.76% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -7661.383% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -456.629% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -16.508% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5383.67% |
| Accustem Sciences Inc. | 1.07 Million USD | -921.881% |
| EV Biologics, Inc. | 2.11 Million USD | -421.427% |
| Q BioMed Inc. | 8.13 Million USD | -35.603% |
| GB Sciences, Inc. | 5.41 Million USD | -103.57% |
| Alpha Cognition Inc. | 7.16 Million USD | -53.927% |
| CSL Limited | 18.62 Billion USD | 99.941% |
| Agentix Corp. | 2.51 Million USD | -339.287% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 90.711% |
| Enzolytics Inc. | 365.26 Million USD | 96.981% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 83.636% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1214.906% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -91.94% |
| argenx SE | 444.95 Million USD | 97.521% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 85.28% |
| HST Global, Inc. | 593.59 Thousand USD | -1757.929% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -543.439% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -775.842% |
| Halberd Corporation | 728.71 Thousand USD | -1413.414% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 55.433% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -200.902% |
| Zenith Capital Corp. | 27.56 Thousand USD | -39903.399% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 7.347% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -195.33% |
| AVAX Technologies, Inc. | 3.99 Million USD | -176.145% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1519.857% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -306.711% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4521.141% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -40.299% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -16377.965% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 78.059% |
| Kadimastem Ltd | 3.5 Million USD | -214.663% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 30.658% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2273.265% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -40101.717% |
| LadRx Corporation | 2.2 Million USD | -401.177% |
| Cell Source, Inc. | 15.8 Million USD | 30.229% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -24574.55% |
| Regen BioPharma, Inc. | 5.45 Million USD | -102.076% |
| Regen BioPharma, Inc. | 5.45 Million USD | -102.076% |
| Affymax, Inc. | 8.87 Million USD | -24.321% |
| Mobile Lads Corp. | 1.31 Million USD | -739.632% |
| Itoco Inc. | 1.65 Million USD | -567.122% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -437.567% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -82.32% |
| International Stem Cell Corporation | 5.27 Million USD | -108.993% |
| CytoDyn Inc. | 127.89 Million USD | 91.377% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -26284.691% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -604.079% |
| Qrons Inc. | 1.48 Million USD | -640.81% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 0.152% |
| SYBLEU INC | 681.41 Thousand USD | -1518.481% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1263.578% |
| Rebus Holdings, Inc. | 5.24 Million USD | -110.388% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -80.739% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1662.285% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -138.862% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 73.099% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 50.467% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -444.515% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -101.324% |
| Neutra Corp. | 973.52 Thousand USD | -1032.841% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 61.99% |
| PureTech Health plc | 125.58 Million USD | 91.218% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -193.537% |
| IXICO plc | 1.9 Million USD | -480.36% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 46.278% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 89.326% |
| CSL Limited | 18.62 Billion USD | 99.941% |
| Cellectis S.A. | 249.36 Million USD | 95.577% |